心房颤动合并中重度功能性二尖瓣反流：导管消融或药物治疗临床疗效的对比研究

赵丹清; 张付涛; 刘晓洁; 吴金涛; 张雷明; 胡娟; 范宪伟; 杨海涛; 严丽洁; 刘静静; 张智文; 王山岭

doi:10.13201/j.issn.1001-1439.2021.10.011

心房颤动合并中重度功能性二尖瓣反流：导管消融或药物治疗临床疗效的对比研究

- 1. 河南大学人民医院河南省人民医院心内科(郑州,450003);
- 2. 河南省人民医院心脏中心华中阜外医院郑州大学华中阜外医院
基金项目:
河南省医学科技攻关计划省部共建项目(No:SBGJ202002030)

河南省科技攻关项目(No:212102310793)

详细信息

通讯作者: 吴金涛,E-mail:wujintao666@126.com

中图分类号: R541.7

收稿日期: 2021-04-30

Atrial fibrillation with moderate to severe functional mitral regurgitation:A comparative study of the clinical outcomes of catheter ablation versus drug therapy

- 1. Department of Cardiology,Henan University People's Hospital,Henan Provincial People's Hospital, Zhengzhou, 450003, China;
- 2. Heart Centre of Henan Provincial People's Hospital,Central China Fuwai Hospital,Central China Fuwai Hospital of Zhengzhou University

More Information

Corresponding author: WU Jintao, E-mail: wujintao666@126.com

Received Date: 30 April 2021

摘要

摘要: 目的:比较心房颤动(atrial fibrillation, AF)合并中、重度功能性二尖瓣反流(mitral regurgitation, MR)患者经导管消融或常规药物治疗的临床疗效,评估导管消融治疗对该类患者临床预后的影响。方法:回顾性分析在我院住院治疗的AF合并中、重度功能性MR的患者151例,根据其住院期间治疗方案分为导管消融组与药物治疗组。为避免两组基线差异对结果的影响,采用倾向性匹配方法,校正年龄、CHA₂DS₂-VASc评分、左室射血分数(left ventricular ejection fraction, LVEF)后,最终纳入43对共86例患者。观察指标为随访期间心力衰竭(心衰)相关住院及复合事件[心衰相关住院、卒中/短暂脑缺血发作(transient ischemic attack, TIA)]发生率。结果:随访期间,导管消融组心衰相关住院年发生率4.9%,卒中/TIA年发生率0%,复合事件年发生率4.9%;药物治疗组心衰相关住院年发生率15.3%,卒中/TIA年发生率1.4%,复合事件年发生率16.7%。随访21.5±8.8(3~36)个月,Kaplan-Meier生存曲线分析显示导管消融组心衰相关住院发生率(log-rank检验,P=0.043)及复合事件发生率(log-rank检验,P=0.026)均显著低于药物治疗组。多因素Cox回归分析发现,导管消融治疗(HR=0.27;95%CI:0.09~0.84;P=0.024)及基线存在心衰(HR=3.84;95%CI:1.07~13.74;P=0.038)是随访期间复合事件发生的独立预测因素。结论:AF合并中、重度功能性MR患者行导管消融治疗较常规药物治疗能显著降低临床事件发生率。
- 心房颤动 /
- 功能性二尖瓣反流 /
- 导管消融
Abstract: Objective: To compare the clinical efficacy of catheter ablation and conventional drug therapy in patients with atrial fibrillation(AF) complicated with moderate to severe functional mitral regurgitation(MR), and to evaluate the effect of catheter ablation on the clinical prognosis.Methods: This retrospective study included 151 consecutive patients with AF and moderate to severe functional MR. According to the treatment plan during hospitalization, all patients were divided into the catheter ablation group and drug therapy group. In order to avoid the impact of baseline differences between the two groups on the results, 43 pairs of 86 patients were finally included after adjusting for age, CHA₂DS₂-VASc scores, and left ventricular ejection fraction(LVEF) using the propensity score matching method. The outcome measures were the incidence of heart failure-related hospitalization and composite events(heart failure-related hospitalization, stroke/transient ischemic attack[TIA]) during follow-up.Results: During the follow-up period, the annual incidence of heart failure-related hospitalization, stroke/TIA, and composite events were 4.9%, 0%, and 4.9% respectively in the catheter ablation group, while were 15.3%, 1.4%, and 16.7% respectively in the drug therapy group. Followed up for 21.5±8.8(3-36) months, Kaplan-Meier survival curve analysis showed that the incidence of heart failure-related hospitalization(log-rank test, P=0.043) and composite events(log-rank test, P=0.026) in the catheter ablation group were significantly lower than those in the drug therapy group. Multivariate Cox regression analysis showed that catheter ablation(HR=0.27; 95%CI: 0.09-0.84; P=0.024) and baseline heart failure(HR=3.84; 95%CI: 1.07-13.74; P=0.038) were independent predictors of composite events during follow-up.Conclusion: Catheter ablation can significantly reduce the incidence of clinical events compared with conventional drug therapy in patients with AF complicated with moderate to severe functional MR.
- atrial fibrillation /
- functional mitral regurgitation /
- catheter ablation

HTML全文

参考文献(17)

[1]	刘美,范琰,刘梅林.老年心房颤动伴二尖瓣反流患者的临床特点和预后[J].临床心血管病杂志,2021,37(5):447-452.
[2]	Agricola E,Ielasi A,Oppizzi M,et al.Long-term prognosis of medically treated patients with functional mitral regurgitation and left ventricular dysfunction[J].Eur J Heart Fail,2009,11(6):581-587.
[3]	Falk V,Baumgartner H,Bax JJ,et al.2017 ESC/EACTS Guidelines for the management of valvular heart disease[J].Eur J Cardiothorac Surg,2017,52(4):616-664.
[4]	Rossi A,Dini FL,Faggiano P,et al.Independent prognostic value of functional mitral regurgitation in patients with heart failure.A quantitative analysis of 1256 patients with ischaemic and nonischaemic dilated cardiomyopathy[J].Heart,2011,97:1675-1680.
[5]	Wu JT,Zaman J,Yakupoglu HY,et al.Catheter ablation of atrial fibrillation in patients with functional mitral regurgitation and left ventricular systolic dysfunction[J].Front Cardiovasc Med,2020,7:596491.
[6]	Lancellotti P,Moura L,Pierard LA,et al.European Association of Echocardiography recommendations for the assessment of valvular regurgitation.Part 2:mitral and tricuspid regurgitation(native valve disease)[J].Eur J Echocardiogr,2010,11(4):307-332.
[7]	Nishimura RA,Otto CM,Bonow RO,et al.2014 AHA/ACC guideline for the management of patients with valvular heart disease:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J].J Am Coll Cardiol,2014,63(22):57-185.
[8]	Hindricks G,Potpara T,Dagres N,et al.2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery(EACTS)[J].Eur Heart J,2021,42(5):373-498.
[9]	中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心力衰竭和心肌病杂志,2018,2(4):196-225.
[10]	Baumgartner H,Falk V,Bax JJ,et al.Michele De Bonis,2017 ESC/EACTS Guidelines for the management of valvular heart disease[J].Kardiol Pol,2018,76(1):1-62.
[11]	Sacco RL,Kasner SE,Broderick JP,et al.An updated definition of stroke for the 21st century:a statement for healthcare professionals from the American Heart Association/American Stroke Association[J].Stroke,2013,44(7):2064-2089.
[12]	Easton JD,Saver JL,Albers GW,et al.Definition and evaluation of transient ischemic attack:a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council;Council on Cardiovascular Surgery and Anesthesia;Council on Cardiovascular Radiology and Intervention;Council on Cardiovascular Nursing;and the Interdisciplinary Council on Peripheral Vascular Disease.The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists[J].Stroke,2009,40(6):2276-2293.
[13]	Agricola E,Ielasi A,Oppizzi M,et al.Long-term prognosis of medically treated patients with functional mitral regurgitation and left ventricular dysfunction[J].Eur J Heart Fail,2009,11(6):581-587.
[14]	Gertz ZM,Raina A,Saghy L,et al.Evidence of atrial functional mitral regurgitation due to atrial fibrillation:reversal with arrhythmia control[J].J Am Coll Cardiol,2011,58(14):1474-1481.
[15]	Udo EO,Hassink RJ.Pulmonary vein isolation as a treatment for severe atrial functional mitral regurgitation in a patient with atrial fibrillation[J].Int J Cardiol,2014,175(3):578-579.
[16]	朱文青,陈庆兴.《2020ESC/EACTS心房颤动诊断与管理指南》更新解读[J].临床心血管病杂志,2020,36(11):975-977.
[17]	Turagam MK,Garg J,Whang W,et al.Catheter ablation of atrial fibrillation in patients with heart failure:a meta-analysis of randomized controlled trials[J].Ann Intern Med,2019,170(1):41-50.